The Pancreatic Enzymes After Gastrectomy Trial

NCT06058442 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2026-01-22

No results posted yet for this study

Summary

This trial evaluates the effects (e.g. on quality of life, weight) of NORTASE® compared to standard care of patients who have undergone gastrectomy.

Conditions

  • Gastrectomy

Interventions

DRUG

NORTASE®

10-15 capsules of NORTASE® per day - over 6 months

DRUG

Placebo

10-15 capsules of placebo per day - over 6 months

Sponsors & Collaborators

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Albrecht Hoffmeister, Prof. Dr. · Universität Leipzig

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06058442 on ClinicalTrials.gov